Press release
Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Polycystic Kidney Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Polycystic Kidney Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Polycystic Kidney Disease Pipeline Report
* In June 2025, Biogen announced a Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Patients will be enrolled in disease specific cohorts within the trial, and effectiveness of bardoxolone methyl in treating CKD will be assessed separately by cohort for each rare CKD.
* DelveInsight's Polycystic Kidney Disease Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Polycystic Kidney Disease treatment.
* The leading Polycystic Kidney Disease Companies such as Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc . and others.
* Promising Polycystic Kidney Disease Pipeline Therapies such as Rapamune, Lisinopril, Telmisartan, Empagliflozin 10 MG, Everolimus, Bosutinib, Tolvaptan MR and others.
Stay ahead with the most recent pipeline outlook for Polycystic Kidney Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Polycystic Kidney Disease Treatment Drugs [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Polycystic Kidney Disease Emerging Drugs Profile
* Tamibarotene: Rege Nephro Co., Ltd.
Tamibarotene, developed by Rege Nephro Co., Ltd., is a retinoic acid receptor (RAR) agonist currently undergoing clinical trials for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This drug, also known by its investigational code RN-014, is designed to inhibit cyst formation and improve renal function in patients suffering from this hereditary condition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Autosomal dominant polycystic kidney disease (ADPKD).
* RGLS8429: Regulus Therapeutics Inc.
RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown data in preclinical models, where improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound, RGLS4326. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Polycystic Kidney Disease.
* AL1311: AceLink Therapeutics, Inc.
AL1311 is a highly potent NRF2 activator that is being developed for Autosomal Dominant Polycystic Kidney disease (ADPKD). AL1311 is different from other electrophilic and reactive NRF2 activators because it works by disrupting the protein-protein interaction between NRF2 and its regulatory protein Keap1. Non-reactive NRF2 activators have the potential to have better specificity for NRF2 activation and therefore a better safety profile. Currently, the drug is in Preclinical stage of development for the treatment of Polycystic Kidney Disease.
The Polycystic Kidney Disease Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Polycystic Kidney Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycystic Kidney Disease Treatment.
* Polycystic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Polycystic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycystic Kidney Disease market
Explore groundbreaking therapies and clinical trials in the Polycystic Kidney Disease Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Drugs for Polycystic Kidney Disease [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Polycystic Kidney Disease Companies
Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc . and others.
Polycystic Kidney Diseases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Polycystic Kidney Disease Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Polycystic Kidney Disease Treatment. Learn about new drugs of Polycystic Kidney Disease, pipeline developments, and key companies with DelveInsight's expert analysis @ Polycystic Kidney Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Polycystic Kidney Disease Pipeline Report
* Coverage- Global
* Polycystic Kidney Disease Companies- Rege Nephro Co., Ltd., Regulus Therapeutics Inc., Vertex Pharmaceuticals Incorporated, AceLink Therapeutics, Inc . and others.
* Polycystic Kidney Disease Pipeline Therapies- Rapamune, Lisinopril, Telmisartan, Empagliflozin 10 MG, Everolimus, Bosutinib, Tolvaptan MR and others.
* Polycystic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Polycystic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Polycystic Kidney Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Polycystic Kidney Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Polycystic Kidney Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Polycystic Kidney Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Tamibarotene: Rege Nephro Co., Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RGLS8429: Regulus Therapeutics Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* AL1311: AceLink Therapeutics, Inc.
* Inactive Products
* Polycystic Kidney Disease Key Companies
* Polycystic Kidney Disease Key Products
* Polycystic Kidney Disease- Unmet Needs
* Polycystic Kidney Disease- Market Drivers and Barriers
* Polycystic Kidney Disease- Future Perspectives and Conclusion
* Polycystic Kidney Disease Analyst Views
* Polycystic Kidney Disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polycystic-kidney-disease-pipeline-appears-robust-with-8-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/polycystic-kidney-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4060406 • Views: …
More Releases from ABNewswire
Pie Launches HMRC-Recognised Tax Return Software for MTD UK 2026
Pie Money Limited has launched its HMRC-recognised self assessment software, positioning Pie as the UK's best tax return solution ahead of Making Tax Digital 2026. With real-time tax calculations, smart bookkeeping, and seamless HMRC integration, Pie helps freelancers, contractors, and small businesses file taxes with confidence, accuracy, and ease.
Dublin, Ireland - 27 August, 2025 - Pie Money Limited, the fintech innovator behind Pie.tax, has today announced the expansion of its…
How Trapping USA Protects Richardson, TX, Families and Pets Through Safe Pest Co …
Trapping USA provides safe and effective pest control in Richardson, TX, using eco-friendly methods that protect families, pets, and the environment from harmful pests.
Richardson, TX - As Richardson, TX, continues to grow, so does the need for effective pest control services that protect both homes and families. Trapping USA is at the forefront of delivering pest control services that prioritize safety, ensuring families and pets remain safe while receiving top-tier…
Pie Launches AI-Powered Upgrade to the Best Tax Return Software in the UK 2025
Designed to provide real-time tax advice, automatic error checks, and personalised filing insights, the AI Assistant strengthens Pie's position as the best self assessment software in the UK. "Tax doesn't need to be complicated," said Tommy McNally, Founder of Pie Money Limited. "With our AI Assistant, we've taken the guesswork out of self assessment.
Dublin, Ireland - 27 August, 2025 - Pie Money Limited, creators of Pie.tax, today announced the launch…
Sydney Tiling Pro Celebrates 17 Years of Excellence as Professional Tilers
Sydney Tiling Pro, a trusted name in residential and commercial tiling across the city, proudly announces its 17th anniversary. Since 2008, the company has been delivering precision craftsmanship, reliable service, and transparent pricing, earning the trust of both homeowners and businesses, and often being referred to as one of the best tilers in Sydney [https://sydneytilingpro.com/] and the surrounding areas.
Over the past 17 years, Sydney Tiling Pro has transformed properties with…
More Releases for Polycystic
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Research
The Global Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market reached with a CAGR during the forecast period 2024-2031.
Autosomal Dominant Polycystic Kidney Disease Market, as detailed in the DataM Intelligence report, presents a strategic overview of the industry backed by in-depth data and market trends. The study highlights the performance and positioning of major players, focusing on their offerings, pricing models, financial outcomes, and growth strategies. It serves as a concise…
Global Efforts to Address Polycystic Ovarian Syndrome (PCOS) Gain Momentum
The Polycystic Ovarian Syndrome (PCOS) Treatment Market is expected to grow from an estimated USD 3514.5 million in 2024 to USD 5546.3 million in 2033, at a CAGR of 5.20%. Global initiatives to raise awareness and address Polycystic Ovarian Syndrome (PCOS) are making significant strides in improving women's health. The World Health Organization (WHO) highlights PCOS as a critical health disorder due to its impact on reproductive health, metabolic well-being,…
Polycystic Kidney Disease Treatment Comprehensive Analysis and Future Estimation …
According to Fact.MR, Insights of Polycystic Kidney Disease Treatment is a specialized and in-depth study of the industry with a special focus on the Key Trends of Polycystic Kidney Disease Treatment as a Service. The report aims to provide an overview with detailed segmentation by type, application, end use and geography. The global is expected to witness high growth during the forecast period.
A survey offers detailed analysis on key growth…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
Global Polycystic Ovary Syndrome Market Trends, Size, Forecast - 2018-2023
Polycystic ovary syndrome is a hormonal disorder observed in females of reproductive ages. The disorder causes the excessive production of hormones in the female body, which include testosterone or androgens, hormones that are primarily associated with the male reproductive system. PCOS includes a range of symptoms such as irregular menstrual cycle, trouble in getting pregnant, cyst formation in the ovaries, excessive body and facial hair, and pelvic pain, among…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
